Article Figures & Data
Figures
- Fig. 1.
In vitro cytotoxicity of PLD versus IL-PLD in various cell lines. Raji (A), Ramos (B), or Jurkat (C) cells were treated with PLD (filled symbol) or IL-PLD (open symbol) for 72 h, then assessed for viability as described in Materials and Methods. Viability is expressed as % of control (nontreated) cells.
- Fig. 2.
Plasma DXR clearance, myelotoxicity, and biodistribution of IL-PLD, PLD, and NL-DXR in xenograft-bearing mice. A, blood samples were taken from IL-PLD–treated (▪), PLD-treated (♦), and NL-DXR–treated (▴) mice (n = 4 per group); blood cells were pelleted; and plasma was collected. DXR was extracted from plasma and quantified. B, mice were treated with 10 mg/kg IL-PLD, PLD, NL-DXR, or PBS (n = 4 per group), and 24 hours later, mice were euthanized and bone marrow cells (BMC) were harvested and counted. C, xenograft-bearing mice were treated with 10 mg/kg IL-PLD (filled columns) or PLD (open columns; n = 4 per group), and 24 hours later, mice were euthanized and organs were harvested, washed, weighed, and the DXR was extracted and quantified.
- Fig. 3.
IL-PLD treatment produced a greater reduction of tumor volume than did PLD with comparable toxicity. Mice were treated with either a single dose of 8 mg/kg (▪), 12 mg/kg (▴), or 16 mg/kg (•) or were treated with three doses of 8 mg/kg (♦) PLD (solid line) or IL-PLD (dashed line; n = 8 per group). Tumor size was assessed twice weekly. All treatment groups were compared with PBS-treated control mice (+). Tumor volumes were compared in mice treated with the various single doses (A) or 8 mg/kg single versus three dose (B). Toxicity assessment included weekly measurements of WBC counts (C) and mice weights (D).
- Fig. 4.
IL-PLD produced more reduction in tumor volume and enhanced survival versus PLD- or HB22.7-conjugated empty liposomes (IL-null). Mice were treated with IL-PLD (♦), PLD (▴), PLD plus unconjugated HB22.7 (•), or IL-null (+) on day 1, 8, and 15 after tumor implantation (n = 8 per group). All groups were compared with PBS-treated control (▪). A, tumor volume. B, survival.
Tables
- Table 1.
χ2 and P values for xenograft studies
PLD vs IL-PLD dose-response study (Fig. 3) χ2 P Ctrl vs 8 mg/kg PLD single dose 0.1454 0.7029 Ctrl vs 12 mg/kg PLD single dose 2.496 0.1141 Ctrl vs 16 mg/kg PLD single dose 7.504 0.0062 Ctrl vs 8 mg/kg 3 doses 3.646 0.0562 Ctrl vs 8 mg/kg IL-PLD single dose 4.795 0.0285 Ctrl vs 12 mg/kg IL-PLD single dose 4.922 0.0265 Ctrl vs 16 mg/kg IL-PLD single dose 7.504 0.0062 Ctrl vs 8 mg/kg IL-PLD 3 doses 7.504 0.0062 PLD vs 8 mg/kg IL-PLD single dose 6.8 0.0091 PLD vs 12 mg/kg IL-PLD single dose 0.7242 0.3948 PLD vs 16 mg/kg IL-PLD single dose 0.02425 0.8762 PLD vs 8 mg/kg IL-PLD 3 doses 7.344 0.0067 8 mg/kg PLD single dose vs 8 mg/kg PLD 3 doses 4.795 0.0285 8 mg/kg IL-PLD single dose vs 8 mg/kg IL-PLD 3 doses 4.268 0.0388 PLD vs IL-PLD vs IL-null study (Fig. 4) χ2 P Ctrl vs PLD 20.5 <0.0001 Ctrl vs IL-PLD 26.5 <0.0001 Ctrl vs PLD + free HB22.7 10.79 0.001 Ctrl vs IL-null 11.48 0.0007 IL-PLD vs PLD 12.94 0.0003 IL-PLD vs PLD + free HB22.7 14.87 0.0001 IL-PLD vs IL-null 9.824 0.0017 PLD vs PLD + free HB22.7 0.3052 0.5806 PLD vs IL-null 0.08097 0.776 IL-null vs PLD + free HB22.7 0.1559 0.693 NOTE: Data were analyzed using the modified Kaplan- Meier curves and the Log-rank test as described in Materials and Methods. Comparisons with significant P values (<0.05) are shown in bold.
Abbreviation: Ctrl, control.
Volume 16, Issue 10
